FY2026 Earnings Forecast for NVO Issued By Erste Group Bank

Novo Nordisk A/S (NYSE:NVO) – Equities research analysts at Erste Group Bank lifted their FY2026 earnings estimates for shares of Novo Nordisk A/S in a research report issued to clients and investors on Wednesday, August 5th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $3.27 for the year, up from their prior forecast of $3.20. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.39 per share.

Several other analysts have also recently issued reports on NVO. Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. BMO Capital Markets reaffirmed a “market perform” rating and set a $47.00 price target on shares of Novo Nordisk A/S in a research note on Thursday. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Finally, Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Five research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $65.81.

Novo Nordisk A/S Trading Up 0.7%

Shares of NVO stock opened at $47.59 on Tuesday. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16. The stock’s 50-day moving average price is $47.07 and its 200-day moving average price is $44.81. The stock has a market capitalization of $212.49 billion, a price-to-earnings ratio of 11.64, a price-to-earnings-growth ratio of 4.31 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be given a dividend of $0.5786 per share. This represents a dividend yield of 254.0%. The ex-dividend date is Monday, August 17th. Novo Nordisk A/S’s payout ratio is 42.79%.

Institutional Investors Weigh In On Novo Nordisk A/S

Several hedge funds and other institutional investors have recently modified their holdings of NVO. Somerville Kurt F purchased a new position in Novo Nordisk A/S during the 2nd quarter valued at $231,000. Trust Co. of Vermont bought a new stake in shares of Novo Nordisk A/S during the second quarter worth $1,250,000. Platform Technology Partners lifted its position in shares of Novo Nordisk A/S by 39.2% during the second quarter. Platform Technology Partners now owns 10,941 shares of the company’s stock worth $525,000 after purchasing an additional 3,079 shares during the last quarter. Fortis Group Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 145.5% during the second quarter. Fortis Group Advisors LLC now owns 72,916 shares of the company’s stock valued at $3,496,000 after purchasing an additional 43,213 shares during the period. Finally, Allen Wealth Management LLC purchased a new stake in shares of Novo Nordisk A/S during the second quarter valued at $205,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Analysts set an average price target of $65.56 for Novo Nordisk, substantially above the stock’s recent trading level near $47.59. If achieved, the target would imply roughly 38% upside and may support buying interest. Analysts Set Novo Nordisk A/S Price Target at $65.56
• Positive Sentiment: Erste Group Bank raised its fiscal 2026 earnings-per-share forecast for Novo Nordisk to $3.27 from $3.20. The revised estimate remains below the $3.39 consensus, but the upward revision signals improving analyst expectations for profitability. Erste Group Bank Raises Novo Nordisk Earnings Estimate
• Positive Sentiment: Novo Nordisk named Amazon Web Services its preferred global cloud and strategic artificial-intelligence partner. A new London innovation hub and AWS tools are intended to accelerate drug discovery, therapy design and clinical-data analysis; more than 25,000 Novo employees have already used the technology. The partnership could improve research efficiency and strengthen the company’s long-term pipeline. Novo Nordisk, Amazon Web Services Collaborate to Advance Drug Discovery for Chronic Diseases
• Positive Sentiment: Veru reported that its semaglutide combination trial is fully enrolled and remains on track for interim results in the first quarter of 2027. Novo Nordisk is supplying clinical product, potentially expanding the use of its semaglutide platform, though the financial impact is not yet clear. Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b Trial Progress
• Neutral Sentiment: Investors continue to compare Novo Nordisk with Eli Lilly as manufacturing capacity becomes a potential competitive advantage in the obesity-drug market. The article highlights both the scale of the opportunity and the intensity of competition. Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.